BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Iovance: Revenue Is Real, the Losses Are Real, and the Pipeline Just Got More Complicated

Moe Alsumidaie by Moe Alsumidaie
November 11, 2026
in Research Notes
0
76
SHARES
1.3k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of its life, Iovance Biotherapeutics was a research project wearing a company’s clothes. It spent years and hundreds of millions of dollars teaching the immune system to fight cancer, with nothing to sell. Then, in early 2024, the FDA approved Amtagvi, the first tumor-infiltrating lymphocyte therapy ever cleared for commercial use, and the company crossed into a different kind of story. Revenue arrived. The losses, though, did not leave.

That tension sits at the center of every recent filing. A business can run at a loss while growing fast and still be on a credible path, if the math is moving in the right direction. The question the latest numbers raise is whether the math is moving fast enough, and whether the pipeline news announced in October and November 2026 changes that calculation.

The story, briefly

Iovance went from essentially zero revenue in 2023 to $264 million in full-year 2025, a genuine commercial launch. The company is still losing more than a dollar for every dollar it earns, meaning the business is not yet self-funding. The stock sits well below its 52-week high even after a strong run over the past year, a gap that reflects real uncertainty about how quickly losses narrow. New clinical data released in late October 2026 showed a striking split: a modest response rate in the broad lung cancer population, and a much higher one in a specific subgroup. Which number the market should believe is the open question.

What the filing shows: growth that still bleeds

The 10-Q for the quarter ended September 30, 2026 is the most recent filed period. Read alongside the full-year 2025 10-K, it tells a consistent story: revenue is growing at a pace that would double the business in roughly 18 months, but costs are growing alongside it. The net margin for 2025 was deeply negative, meaning that for every dollar Amtagvi brought in, the company spent about two and a half dollars in total. That is an improvement from the prior year, which is itself the right direction, but the distance left to travel is large.

BullScope TerminalIOVA was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Think of it this way: a restaurant that takes in $264 from a table but spends $660 to serve it is not yet a restaurant, it is a very expensive cooking school. The question is always whether the tuition eventually stops.

The loss per share has also been narrowing each year, each year a smaller bite out of the company’s cash. That trend is real and filed. What the filings cannot tell us is when the line crosses zero, and the dossier does not provide current cash balance figures, so we cannot say how many years of runway remain at the current burn rate.

The lung cancer data: two numbers that should not coexist

On October 29, 2026, Iovance released updated Phase 2 results for lifileucel in previously treated non-squamous metastatic lung cancer. Among the patients in the broad trial population, roughly one in four responded to treatment, meaning their tumors shrank by a measurable amount. That is meaningful in a disease where options are limited, but it is not a transformative result.

Inside that same trial, researchers identified a retrospective subgroup defined by specific biomarkers and smoking history. In that group, the response rate was 59.1%, more than double. Nearly six in ten patients responded, compared to roughly one in four across the full population.

Those two figures sitting side by side are the tension. A response rate approaching sixty percent in a well-defined subgroup is the kind of signal that can support a new indication and a much larger market. A one-in-four rate in an unselected population is harder to build a commercial franchise around. The critical word is “retrospective”: the subgroup was identified after the fact, by looking back at who responded and asking what they had in common. That method can find real signals, but it can also find patterns that dissolve when tested prospectively.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: IOVA and 500+ other names, on the same official data.See the evidence engine →

Iovance knows this. The company announced that enrollment for the POSITILITY trial, which will test the biomarker-enriched approach prospectively, is set to begin in November 2026, with a supplemental FDA application for lung cancer planned for 2027. A prospective trial is the only way to confirm whether the higher figure is a discovery or a statistical artifact.

What else is moving in the pipeline

Amtagvi also received Fast Track Designation from the FDA for soft tissue sarcomas, as reported in the August 2026 quarterly filing. Fast Track is a process designation, not an approval, but it means the FDA has agreed to work more closely with the company on the development path, which can shorten the time to a decision. Sarcomas are rare and difficult to treat, and an approval there would open a market that Amtagvi’s current melanoma label does not reach.

Earlier-stage programs, IOV-4001 and IOV-5001, are in Phase 1 and 2 trials for melanoma, lung cancer, and other solid tumors. These are years from any commercial decision and carry the full uncertainty of early-phase oncology work. Initial data from investigator-sponsored trials in two additional skin cancers are expected in the first half of 2027.

Reading the numbers

  • $264 million, FY2025 revenue. What it is: total product sales for the full year ended December 31, 2025, the first full commercial year for Amtagvi. What it means here: the launch is real and accelerating, up 61% from 2024’s $164 million. In everyday terms: a business that earned roughly $13 per hour in 2024 was earning about $21 per hour by 2025, same product, more hospitals using it.
  • Negative 148%, net margin for 2025. What it is: for every dollar of revenue, the company lost $1.48 after all costs. What it means here: the business is not yet self-sustaining, though the loss rate is shrinking each year. In everyday terms: a household earning $50,000 but spending $124,000 is not going broke today if it has savings, but the savings question matters enormously.
  • 24.6% vs. 59.1%, lung cancer response rates. What it is: the share of patients whose tumors shrank meaningfully in the broad trial versus a biomarker-selected subgroup, as of October 14, 2026. What it means here: the gap between these two figures is the entire commercial argument for the lung cancer expansion. If the prospective POSITILITY trial confirms the higher number, the addressable market grows substantially. If it reverts toward the lower number, the 2027 FDA application becomes harder to build.
  • $8.08, current share price, down 46% from the 52-week high. What it is: the market’s current price tag on the whole company, after a year in which the stock tripled. What it means here: the mood (what investors are currently paying) has cooled sharply from its peak even as the math (filed revenue growth and narrowing losses) has continued to improve. That divergence is not a recommendation in either direction; it is the fact that makes the story worth reading.

Sources

  • 10-Q, quarter ended September 30, 2026
  • 10-Q, quarter ended June 30, 2026
  • 10-K, fiscal year ended December 31, 2025
  • 10-K, fiscal year ended December 31, 2024
  • Iovance October 29, 2026 clinical data release
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read IOVA’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arvinas: the first PROTAC approved, and almost nothing left to show for it

by Moe Alsumidaie
November 13, 2026
0

Five years ago, Arvinas collected $650 million in a single wire transfer from Pfizer, the largest upfront payment any biotech had received for a drug that had not...

Read moreDetails

Jushi Holdings: $215 Million in Debt, $31 Million in Cash, and a Bet on Virginia

by Moe Alsumidaie
November 12, 2026
0

Jushi went public in December 2019 with a simple pitch: buy dispensary licenses in states before adult-use legalization arrived, then ride the wave. For a few years the...

Read moreDetails

Merck Is Spending Like It Has a Problem. The Filed Numbers Say It Does.

by Moe Alsumidaie
November 11, 2026
0

For most of the last decade, Merck ran a tidy business: one blockbuster drug, Keytruda, growing fast enough to carry everything else. Then 2026 arrived, and the company...

Read moreDetails

Ligand Pharmaceuticals: Royalties Are Surging. The Stock Price Assumes They Never Stop.

by Moe Alsumidaie
November 6, 2026
0

Ligand spent most of the last decade shedding things. It spun off its antibody discovery unit in November 2022, sold assets, and narrowed toward a single idea: own...

Read moreDetails

Harrow: Revenue Doubles, Equity Nearly Vanishes, and the Stock Is Down by Half

by Moe Alsumidaie
November 11, 2026
0

The quick read Harrow's filed numbers show revenue growing at a pace most pharmaceutical companies never see, more than fivefold in five years. The 10-Q filed for the...

Read moreDetails
Next Post

Evidence Sheet: Harrow (HROW)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

October 22, 2026

Organon at $13.90: The Price That Assumes a Soft Landing the Filings Don’t Quite Confirm

November 16, 2026

Energy is up 14.7%. Jobs just turned negative. The same economy produced both.

August 12, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.